Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial

被引：8

作者：

de Marinis, Filippo ^{[1
,2
]}

Vergnenegre, Alain ^{[3
]}

Passaro, Antonio ^{[1
,2
]}

Dubos-Arvis, Catherine ^{[4
]}

Carcereny, Enric ^{[5
]}

Drozdowskyj, Ana ^{[6
]}

Zeaiter, Ali ^{[7
]}

Perez-Moreno, Pablo ^{[7
]}

Rosell, Rafael ^{[5
]}

机构：

[1] European Inst Oncol, Div Thorac Oncol, Milan, Italy

[2] High Specializat Hosp, Rome, Italy

[3] CHU Limoges, Hop Cluzeau, Limoges, France

[4] Ctr Francois Baclesse, F-14021 Caen, France

[5] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain

[6] Pivotal SL, Madrid, Spain

[7] F Hoffmann La Roche, Basel, Switzerland

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 03期

关键词：

EGFR; erlotinib; non-small-cell lung cancer; rash; safety; QUALITY-OF-LIFE; OPEN-LABEL; PHASE-III; CUTANEOUS TOXICITIES; 1ST-LINE TREATMENT; SKIN TOXICITIES; CHEMOTHERAPY; MULTICENTER; CARBOPLATIN; CTONG-0802;

D O I：

10.2217/fon.14.269

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: This analysis investigates incidence and time course of rash in the EURTAC study. Materials & methods: Patients with EGFR mutation-positive non-small-cell lung cancer were randomized 1:1 to receive once daily erlotinib or 3-weekly cycles of chemotherapy. Results: Of the 86 erlotinib-treated patients, 71 reported rash. Median time to first rash appearance was 0.7 months. Most patients (n = 65) had the same or lower grade rash at final assessment compared with initial assessment. Of the 21 patients with decreased rash grade between initial and final assessments, 61.9% received no erlotinib dose modification, 42.8% had no concomitant rash treatment. Conclusion: Most rash cases were mild, occurred within 1 month of erlotinib treatment, and rapidly improved without the need for erlotinib dose alterations.

引用

页码：421 / 429

页数：9

共 26 条

[1] Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21 [J].

Bezjak, Andrea ;

Tu, Dongsheng ;

Seymour, Lesley ;

Clark, Gary ;

Trajkovic, Aleksandra ;

Zukin, Mauro ;

Ayoub, Joseph ;

Lago, Sergio ;

de Albuquerque Ribeiro, Ronaldo ;

Gerogianni, Alexandra ;

Cyjon, Arnold ;

Noble, Jonathan ;

Laberge, Francis ;

Chan, Raymond Tsz-Tong ;

Fenton, David ;

von Pawel, Joachim ;

Reck, Martin ;

Shepherd, Frances A. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) :3831-3837

[2] Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management [J].

Chanprapaph, K. ;

Vachiramon, V. ;

Rattanakaemakorn, P. .

DERMATOLOGY RESEARCH AND PRACTICE, 2014, 2014

[3] Quaity of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) [J].

Chen, G. ;

Feng, J. ;

Zhou, C. ;

Wu, Y. -L. ;

Liu, X. -Q. ;

Wang, C. ;

Zhang, S. ;

Wang, J. ;

Zhou, S. ;

Ren, S. ;

Lu, S. ;

Zhang, L. ;

Hu, C. -P. ;

Hu, C. ;

Luo, Y. ;

Chen, L. ;

Ye, M. ;

Huang, J. ;

Zhi, X. ;

Zhang, Y. ;

Xiu, Q. ;

Ma, J. ;

Zhang, L. ;

You, C. .

ANNALS OF ONCOLOGY, 2013, 24 (06) :1615-1622

[4] Drug therapy: EGFR antagonists in cancer treatment [J].

Ciardiello, Fortunato ;

Tortora, Giampaolo .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1160-1174

[5] The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial [J].

Costa, Carlota ;

Molina, Miguel Angel ;

Drozdowskyj, Ana ;

Gimenez-Capitan, Ana ;

Bertran-Alamillo, Jordi ;

Karachaliou, Niki ;

Gervais, Radj ;

Massuti, Bartomeu ;

Wei, Jia ;

Moran, Teresa ;

Majem, Margarita ;

Felip, Enriqueta ;

Carcereny, Enric ;

Garcia-Campelo, Rosario ;

Viteri, Santiago ;

Taron, Miquel ;

Ono, Mayumi ;

Giannikopoulos, Petros ;

Bivona, Trever ;

Rosell, Rafael .

CLINICAL CANCER RESEARCH, 2014, 20 (07) :2001-2010

[6]

Deplanque G, 2010, J CLIN ONCOL, V28

[7] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors [J].

Gazdar, A. F. .

ONCOGENE, 2009, 28 :S24-S31

[8] Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients [J].

Gerber, Peter Arne ;

Meller, Stephan ;

Eames, Tatiana ;

Buhren, Bettina Alexandra ;

Schrumpf, Holger ;

Hetzer, Sonja ;

Ehmann, Laura Maximiliane ;

Budach, Wilfried ;

Boelke, Edwin ;

Matuschek, Christiane ;

Wollenberg, Andreas ;

Homey, Bernhard .

EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2012, 17

[9]

Hirsh V, 2011, CURR ONCOL, V18, P126

[10] Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non-small cell lung cancer [J].

Kiyohara, Yoshio ;

Yamazaki, Naoya ;

Kishi, Akiko .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 69 (03) :463-472

← 1 2 3 →